These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30130377)

  • 1. Using routinely collected laboratory data to identify high rifampicin-resistant tuberculosis burden communities in the Western Cape Province, South Africa: A retrospective spatiotemporal analysis.
    McIntosh AI; Jenkins HE; White LF; Barnard M; Thomson DR; Dolby T; Simpson J; Streicher EM; Kleinman MB; Ragan EJ; van Helden PD; Murray MB; Warren RM; Jacobson KR
    PLoS Med; 2018 Aug; 15(8):e1002638. PubMed ID: 30130377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of Failure to Routinely Diagnose Resistance to Second-Line Drugs in Patients With Rifampicin-Resistant Tuberculosis on Xpert MTB/RIF: A Multisite Observational Study.
    Jacobson KR; Barnard M; Kleinman MB; Streicher EM; Ragan EJ; White LF; Shapira O; Dolby T; Simpson J; Scott L; Stevens W; van Helden PD; Van Rie A; Warren RM
    Clin Infect Dis; 2017 Jun; 64(11):1502-1508. PubMed ID: 28199520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis.
    Mvelase NR; Balakrishna Y; Lutchminarain K; Mlisana K
    BMJ Open; 2019 Nov; 9(11):e031663. PubMed ID: 31699736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spatial heterogeneity of extensively drug resistant-tuberculosis in Western Cape Province, South Africa.
    Sy KTL; Leavitt SV; de Vos M; Dolby T; Bor J; Horsburgh CR; Warren RM; Streicher EM; Jenkins HE; Jacobson KR
    Sci Rep; 2022 Jun; 12(1):10844. PubMed ID: 35760977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of drug-resistant tuberculosis and imputed burden in South Africa: a national and sub-national cross-sectional survey.
    Ismail NA; Mvusi L; Nanoo A; Dreyer A; Omar SV; Babatunde S; Molebatsi T; van der Walt M; Adelekan A; Deyde V; Ihekweazu C; Madhi SA
    Lancet Infect Dis; 2018 Jul; 18(7):779-787. PubMed ID: 29685458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of compensatory evolution in the emergence and transmission of rifampicin-resistant Mycobacterium tuberculosis in Cape Town, South Africa: a genomic epidemiology study.
    Goig GA; Menardo F; Salaam-Dreyer Z; Dippenaar A; Streicher EM; Daniels J; Reuter A; Borrell S; Reinhard M; Doetsch A; Beisel C; Warren RM; Cox H; Gagneux S
    Lancet Microbe; 2023 Jul; 4(7):e506-e515. PubMed ID: 37295446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular detection and characterization of resistant genes in Mycobacterium tuberculosis complex from DNA isolated from tuberculosis patients in the Eastern Cape province South Africa.
    Bhembe NL; Nwodo UU; Govender S; Hayes C; Ndip RN; Okoh AI; Green E
    BMC Infect Dis; 2014 Sep; 14():479. PubMed ID: 25186245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study.
    Cox H; Dickson-Hall L; Ndjeka N; Van't Hoog A; Grant A; Cobelens F; Stevens W; Nicol M
    PLoS Med; 2017 Feb; 14(2):e1002238. PubMed ID: 28222095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance.
    Van Deun A; Decroo T; Kya Jai Maug A; Hossain MA; Gumusboga M; Mulders W; Ortuño-Gutiérrez N; Lynen L; de Jong BC; Rieder HL
    PLoS One; 2020; 15(5):e0233500. PubMed ID: 32421749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and factors associated with multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana.
    Tembo BP; Malangu NG
    BMC Infect Dis; 2019 Sep; 19(1):779. PubMed ID: 31492099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.
    Espinal MA; Kim SJ; Suarez PG; Kam KM; Khomenko AG; Migliori GB; Baéz J; Kochi A; Dye C; Raviglione MC
    JAMA; 2000 May; 283(19):2537-45. PubMed ID: 10815117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Travel distance to rifampicin-resistant tuberculosis treatment and its impact on loss to follow-up: the importance of continued RR-TB treatment decentralization in South Africa.
    McNabb KC; Bergman AJ; Patil A; Lowensen K; Mthimkhulu N; Budhathoki C; Perrin N; Farley JE
    BMC Public Health; 2024 Feb; 24(1):578. PubMed ID: 38389038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors contributing to the high prevalence of multidrug-resistance/Rifampicin-resistance in patients with tuberculosis: an epidemiological cross sectional and qualitative study from Khabarovsk krai region of Russia.
    Bykov I; Dyachenko O; Ratmanov P; Liu H; Liang L; Wu Q
    BMC Infect Dis; 2022 Jul; 22(1):612. PubMed ID: 35831812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and factors associated with multidrug-resistant tuberculosis in South India.
    Shivekar SS; Kaliaperumal V; Brammacharry U; Sakkaravarthy A; Raj CKV; Alagappan C; Muthaiah M
    Sci Rep; 2020 Oct; 10(1):17552. PubMed ID: 33067551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost per patient of treatment for rifampicin-resistant tuberculosis in a community-based programme in Khayelitsha, South Africa.
    Cox H; Ramma L; Wilkinson L; Azevedo V; Sinanovic E
    Trop Med Int Health; 2015 Oct; 20(10):1337-45. PubMed ID: 25975868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 5-year outcome of multidrug resistant tuberculosis patients in the Cape Province of South Africa.
    Schaaf HS; Botha P; Beyers N; Gie RP; Vermeulen HA; Groenewald P; Coetzee GJ; Donald PR
    Trop Med Int Health; 1996 Oct; 1(5):718-22. PubMed ID: 8911459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rifampicin mono-resistance in Mycobacterium tuberculosis in KwaZulu-Natal, South Africa: a significant phenomenon in a high prevalence TB-HIV region.
    Coovadia YM; Mahomed S; Pillay M; Werner L; Mlisana K
    PLoS One; 2013; 8(11):e77712. PubMed ID: 24223122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential contribution of HIV during first-line tuberculosis treatment to subsequent rifampicin-monoresistant tuberculosis and acquired tuberculosis drug resistance in South Africa: a retrospective molecular epidemiology study.
    Cox H; Salaam-Dreyer Z; Goig GA; Nicol MP; Menardo F; Dippenaar A; Mohr-Holland E; Daniels J; Cudahy PGT; Borrell S; Reinhard M; Doetsch A; Beisel C; Reuter A; Furin J; Gagneux S; Warren RM
    Lancet Microbe; 2021 Nov; 2(11):e584-e593. PubMed ID: 34766068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment initiation among persons diagnosed with drug resistant tuberculosis in Johannesburg, South Africa.
    Evans D; Schnippel K; Govathson C; Sineke T; Black A; Long L; Berhanu R; Rosen S
    PLoS One; 2017; 12(7):e0181238. PubMed ID: 28746344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.